Download Unlocking the Parathyroid Puzzle: A Detailed Look at

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Positron emission tomography wikipedia , lookup

Image-guided radiation therapy wikipedia , lookup

Nuclear medicine wikipedia , lookup

Medical imaging wikipedia , lookup

Transcript
Unlocking the Parathyroid Puzzle: A
Detailed Look at the Multimodality
Options
FAULKNER, A. GIBBS, W.
EEDE-168

No disclosures
Educational Objectives

Increase your knowledge of the relevant anatomy and
pathophysiology of hyperparathyroidism

Discover the multimodality imaging options for
evaluating hyperparathyroidism:
 Sestamibi
 4D
scintigraphy
CT
 Ultrasound
 MRI
Embryology

Typically 2 superior and 2 inferior glands

Superior glands
 Derived
from 4th pharyngeal (brachial) pouch along with
the lateral thyroid lobes

Inferior glands
 Derived
from 3rd pharyngeal (brachial) pouch along with
the thymus
Anatomy

Superior gland
 More
consistent location
 90%
located deep to mid portion of the superior
pole of the thyroid lobe
 4%
deep to mid pole, 3% at or above most superior
point 1% retropharyngeal, 1% retroesophageal,
<1% intrathryoidal
Anatomy

Inferior gland
 More
variable location
 69%
inferior, posterior or lateral to lower thyroid pole
 26%
along the course of the thymus from lower neck
to cervical portion of thymus
 2%
anterior mediastinum with the thymus or inferior
to the thymus <1%
 Rarely
cranial to the superior glands
Anatomy

Average size 5 x 3 x 1 mm

Average weight 40-50 grams

Adenoma mass greater than 10 times normal

Hyperplastic glands of variable size/weight
Pathophysiology

Produce parathyroid hormone (PTH)

Increases calcium level by
↑
renal tubular absorption of calcium
↓
tubular reabsorption of phosphate
↑
osteoclasts
↑
Vit D production → ↑ GI absorption of calcium
Pathophysiology

Primary hyperparathyroidism
↑
Ca++ ↑ PTH
 Typically
seen in 50-70 year old patients
 F>M
 89%
single adenoma
 6%
hyperplasia of all 4 glands
 4%
double adenoma
 Increased
incidence in MEN I and MEN IIA
Treatment

The trend of utilizing minimally invasive
parathyroidectomy with resultant cure rate of 99.4%
(complication rate 1.45%) puts greater emphasis on
accurate pre-operative localization as opposed to
conventional exploration with bilateral cervical
dissection (cure rate 97.1% and complication rate
3.1%)
What are the options for preoperative localization?

Nuclear medicine Sestamibi scintigraphy

Ultrasound
 Grey
scale
 Contrast-enhanced

4D CT

MRI
What are the options for preoperative localization?

Sestamibi and ultrasound
 Similar
sensitivities and specificities for solitary adenoma
detection individually
 Most
commonly used imagining techniques currently
employed

4D CT and MRI
 Typically
used after failed parathyroidectomy or
discordance between sestamibi and ultrasound
Sestamibi Scintigraphy

A meta-analysis of 20,225 cases of primary hyperparathyroidism reported
99mTc sestamibi was: 88.44% sensitive for solitary adenoma, 44.46% for
multiple gland hyperplasia, and 29.95% for double adenoma.
 99mTc
Sestamibi taken up by normal thyroid and parathyroid glands, with
more avid and prolonged retention in parathyroid adenomas and
parathyroid hyperplasia

Improvement in visualization using delayed 2 hour technique, SPECT,
subtraction of 99mTc pertechnetate which is only taken up by the thyroid
gland

Limited scintigraphic resolution for smaller adenomas <500 grams

Few studies have shown little benefit with combination with SPECT/CT with
exception to localization of ectopic parathyroid glands.
Sestamibi Scintigraphy
Pertechnetate image (top left) demonstrates uptake in expected physiologic locations including
the thyroid gland. Sestamibi images taken every ten minutes for one hour demonstrate a focus
of tracer uptake below the inferior pole of the left thyroid lobe compatible with a parathyroid
adenoma. Appreciate the prolonged retention of the sestamibi in the parathyroid adenoma
relative to the thyroid gland.
Sestamibi Scintigraphy
Pertechnetate image (top left) in Patient X demonstrates uptake in expected physiologic locations
including the thyroid gland. Sestamibi images demonstrate a focus of tracer uptake below the
inferior pole of the left thyroid lobe compatible with a parathyroid adenoma (white arrow). Notice
the physiologic cardiac uptake on the sestamibi images (yellow arrow).
Ultrasound

Traditional grey scale and color Doppler sensitivities reportedly 78%
for single adenomas, 16% for double adenomas, and 35% for
multiple-gland hyperplasia

Solitary adenoma - Homogeneous, hypoechoic, hypervascular mass

Cervical lymph node often mimics parathyroid adenoma

Hyperplasia more difficult to visualize given smaller size

Ectopic location in mediastinum or retrotracheal adenoma difficult to
detect

Peripheral rim of vascularity on color Doppler - extrathyroidal feeding
vessel (typically inferior thyroidal artery branch), which enters the
pole of the parathyroid adenoma
Ultrasound
Grey scale sonographic images
demonstrate an oval, hypoechoic
mass posterior to the right
thyroid lobe compatible with a
pathologically proven parathyroid
adenoma.
Ultrasound
Gray scale (left) and
color Doppler (right) in
long (top) and
transverse (bottom)
dimensions
demonstrate an oval
hypoechoic mass with
feeding vessel entering
at the pole with
peripheral arc of
increased vascularity
located inferior to the
left thyroid lobe.
Notice the lack of fatty
hilum and central
feeding artery which
would be seen in a
lymph node.
Contrast-Enhanced Ultrasound

Early European studies demonstrate improved sensitivity
and specificity in confirming suspected adenomas

CEUS utilizes a non-nephrotoxic perfluoro microbubble
contrast agent

Adenomas demonstrate early arterial enhancement with
late phase washout

Improved differentiation between parathyroid adenomas
and thyroid nodules or lymph nodes
Contrast Enhanced Ultrasound
Hypoechoic parathyroid adenoma on grey scale ultrasound (left)
demonstrating homogeneous arterial enhancement after
contrast administration (right).
4D CT

3 dimensions: Multiplanar axial CT with coronal and sagittal
reformats

4th dimension: time – change in enhancement over time in noncontrast, arterial and delayed venous phases

Investigate arterial phase for eutopic or ectopic suspicious
lesions

Review all phases for:
 Noncontrast
 Arterial
 Delayed

– density lower than thyroid gland
phase – avid enhancement
phase – rapid washout
High accuracy for single and multigland detection
4D CT
Noncontrast (left), arterial phase (middle) and delayed phase (right)
axial images through the thyroid gland demonstrate a soft tissue
density nodule located posterior to the right thyroid gland that
enhances on arterial images and exhibits wash out on delayed images.
MRI

Similar sensitivity compared to other imaging modalities

Compared to normal thyroid, parathyroid adenomas are:
 T1
iso to hypointense
 T2
hyperintense
 Often
enhance
 Enhancement
increases sensitivity of atypical T1 and T2
isointense adenoma detection

Pitfall – lymph nodes have similar signal characteristics
MRI
Axial T2, T1 and T1 FS Post contrast images (top)
demonstrate a T2 hyperintense, T1 isointense,
enhancing parathyroid adenoma in the left anterior
mediastinum, inferior to the left thyroid lobe
MRI
Axial T2, T1 and T1 FS Post contrast images (top
three) and coronal T1 FS Post contrast (top right)
and coronal T2 (bottom right) demonstrate a T2
hyperintense, T1 isointense, enhancing parathyroid
adenoma inferior to the left thyroid lobe
Summary

Traditionally used methods - Sestamibi scintigraphy
and ultrasound – remain first line imaging modalities

4D-CT shows great promise, and there is increasing
utilization of this modality

There is a potential future role for contrast-enhanced
ultrasound, which will improve sensitivity and
specificity when added to grey scale and color Doppler
ultrasound
References

Lopez Hanninen E, Vogl TJ, Steinmüller T et al. Preoperative contrast-enhanced MRI of the parathyroid glands in
hyperparathyroidism. Invest Radiol. 2000 Jul;35(7):426-30.

Johnson N, Tublin M, Ogilvie J. Parathyroid Imaging: Technique and Role in the Preoperative Evaluation of Primary
Hyperparathyroidism. AJR 2007 188:6, 1706-1715

Suh YJ, Choi J, Kim S et al. Comparison of 4D CT, ultrasonography, and 99mTc sestamibi SPECT/CT in localizing single-gland
primary hyperparathyroidism. Otolaryngol Head Neck Surg 2015;152:3:438-443

Agha A, Hornung M, Stroszcyznski C et al. Highly Efficient Localization of Pathological Glands in Primary Hyperparathyroidism
Using Contrast-Enhanced Ultrasonography (CEUS) in Comparison With Conventional Ultrasonography. J Clin Endocrinol Metab,
2013, 98 (5);2019-2025.

Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with
primary hyperparathyroidism. Ann Surg. 2011 Mar;253(3):585-91.

Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from
1995 to 2003. Otolaryngol Head Neck Surg. 2005 Mar;132(3):359-72.

McDermott V, Fernandez R, Meakem T, Stolpen A. Preoperative MR imaging in hyperparathyroidism: results and factors affecting
parathyroid detection. AJR 1996 166:3, 705-710

Gayed I, Kim EE, Broussard WF, Evans D. The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of
parathyroid adenomas or hyperplasia. J Nucl Med. 2005 Feb;46(2):248-52.

Ishibashi M, Nishida H, Hiromatsu Y, Kojima K. Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound
and MRI for localization of abnormal parathyroid glands. J Nucl Med. 1998 Feb;39(2):320-4.

Hoang JK, Sung W, Bahl M, Phillips D. How to Perform Parathyroid 4D CT: Tips and Traps for Technique and Interpretation.
Radiology 2014 270:1, 15-24

Chazen J, Gupta A, Dunning A, Phillips CD. Diagnostic Accuracy of 4D-CT for Parathyroid Adenomas and HyperplasiaAJNR Am J
Neuroradiol 2012 Marr; 33:429 –33